<DOC>
	<DOCNO>NCT01421004</DOCNO>
	<brief_summary>This multi-center , open-label , two way crossover study design test bioequivalence 2 different oral form TKI258 , FMI capsule FMI tablet patient advance solid tumor , exclude breast cancer . The aim test demonstrate 2 formulation consider intent purpose make sure act body strength absorb similar amount body . During bioequivalence phase , patient take orally daily dose 500 mg one formulation TKI258 first 3 week treatment 5 day on/2days dose schedule , time , patient switch alternate formulation one additional week . After bioequivalence phase , patient may continue take orally daily dose 500 mg TKI258 FMI capsule formulation disease progression ( assessed RECIST 1.1 ) , unacceptable toxicity , death discontinuation study treatment reason .</brief_summary>
	<brief_title>Bioequivalence 2 Formulations TKI258 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Patients histopathologically cytopathologically confirm diagnosis advance solid tumor , exclude breast cancer , progress despite standard therapy , standard therapy exist 2 . ECOG performance status ( PS ) 0 , 1 2 3 . Patients must meet protocolspecified laboratory value 1 . Patients brain metastases 2 . Patients concurrent severe and/or uncontrolled medical condition could compromise participation study 3 . Patients recover previous anticancer therapy 4 . Patients expect receive prohibited medication bioequivalence phase study 5 . Female patient pregnant , breast feeding 6 . Fertile male woman childbearing potential willing use two highly effective method contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>phase I</keyword>
	<keyword>crossover</keyword>
	<keyword>bioequivalence</keyword>
</DOC>